Researchers from the Institute of Industrial Science, The University of Tokyo have developed ultrathin, stretchable facial electrodes that are effectively invisible and cannot be felt when worn. The electrodes reduce the visual discomfort and psychological burden associated with conventional facial sensors, allowing eye movements, facial muscle activity, and brain activity to be measured under more natural conditions. The electrodes could allow future technology to be operated with subtle facial and eye signals.

In preclinical tests, the compound from UC San Diego startup Sinopia Biosciences boosted the standard treatment’s benefits while counteracting debilitating side effects.

 New data on breastfeeding initiation across the U.S. reveal broad geographic patterns as well as local factors that can inform targeted public health interventions. The study by Tony Grubesic from the University of California Riverside and colleagues was published July 15, 2026, in the open-access journal PLOS Global Public Health.

BUFFALO, NY — July 15, 2026 — A new case report was published in Volume 13 of Oncoscience on May 22, 2026, titled “Cervical angioleiomyoma: A rare tumor behind persistent menorrhagia and pelvic pain.”

Texas A&M University researchers use a naturally occurring gut chemical to heal the brain after traumatic injury, making post traumatic seizures rarer and harder to trigger while pointing toward a future where epilepsy may be prevented before it begins

AMHERST, Mass. — Chang Liu, associate professor in the Riccio College of Engineering at the University of Massachusetts Amherst, wants people to have access to at-home HIV tests sensitive enough for early diagnosis comparable to—or exceeding—lab standards. A new two-year, $1.3 million award from the National Institutes of Health will help him advance his proof-of-concept work toward commercialization. 

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular carcinoma (HCC) would most benefit from combination treatment using immunotherapy and a targeted therapy that blocks the growth signals that the tumor depends on. The work, supported in part by the National Institutes of Health, was published online July 14 in the Proceedings of the National Academy of Sciences.